Moderna Inc (MRNA)
125.65
+14.19
(+12.73%)
USD |
NASDAQ |
May 02, 16:00
123.00
-2.65
(-2.11%)
After-Hours: 20:00
Moderna Research and Development Expense (TTM): 4.845B for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.845B |
| September 30, 2023 | 4.65B |
| June 30, 2023 | 4.31B |
| March 31, 2023 | 3.872B |
| December 31, 2022 | 3.295B |
| September 30, 2022 | 2.732B |
| June 30, 2022 | 2.433B |
| March 31, 2022 | 2.144B |
| December 31, 2021 | 1.991B |
| September 30, 2021 | 2.102B |
| June 30, 2021 | 1.925B |
| Date | Value |
|---|---|
| March 31, 2021 | 1.656B |
| December 31, 2020 | 1.37B |
| September 30, 2020 | 728.64M |
| June 30, 2020 | 504.28M |
| March 31, 2020 | 480.59M |
| December 31, 2019 | 496.00M |
| September 30, 2019 | 528.78M |
| June 30, 2019 | 518.20M |
| March 31, 2019 | 494.37M |
| December 31, 2018 | 454.08M |
| September 30, 2018 | 421.48M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
480.59M
Minimum
Mar 2020
4.845B
Maximum
Dec 2023
2.136B
Average
1.991B
Median
Dec 2021
Research and Development Expense (TTM) Benchmarks
| Eli Lilly and Co | 9.851B |
| Merck & Co Inc | 30.25B |
| Pfizer Inc | 10.68B |
| Johnson & Johnson | 15.30B |
| Novavax Inc | 737.50M |